Rare disease breakthrough: The FDA has approved levacetylleucine (AQNEURSA) for ataxia-telangiectasia (A-T), the first therapy specifically for this condition, based on a phase 3 trial. Diabetes & endurance: A small study using continuous glucose monitoring suggests people with type 1 diabetes can safely finish marathons with finishing times similar to runners without diabetes. Food & climate risk: An El Niño pattern could disrupt fruit and vegetable harvests in major producing regions, with knock-on effects for UK supermarket supply and prices. Heart health nutrition: A new review in the European Heart Journal links higher whole-grain intake with better heart-health markers, including weight, blood pressure and cholesterol. Public health under strain: Gaza’s health system is warning of “slow collapse” as fuel, spare parts and medicines run low, threatening hospital power and services. Infectious disease alert: Germany reports a rare “airport malaria” cluster near Frankfurt, with multiple deaths tied to mosquito-borne infection. Policy & prevention: The EU is moving toward stricter rules for children’s social media access, including age limits and limits on AI chatbot use. Wellness trend: HYROX continues to grow, bringing 16,000 competitors to Salt Lake City with a mix of running and functional fitness stations.